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In gestational diabetes mellitus (GDM), women are unable to compensate for the increased insulin resistance 
during pregnancy. Data are limited regarding the pharmacodynamic effects of metformin and glyburide during 
pregnancy. This study characterized insulin sensitivity (SI), β-cell responsivity, and disposition index (DI) in women
with GDM utilizing a mixed-meal tolerance test (MMTT) before and during treatment with glyburide monotherapy 
(GLY, n = 38), metformin monotherapy (MET, n = 34), or GLY and MET combination therapy (COMBO; n = 36). GLY 
significantly decreased dynamic β-cell responsivity (31%). MET and COMBO significantly increased SI (121% and
83%, respectively). Whereas GLY, MET, and COMBO improved DI, metformin (MET and COMBO) demonstrated a 
larger increase in DI (P = 0.05) and a larger decrease in MMTT peak glucose concentrations (P = 0.03) than subjects 
taking only GLY. Maximizing SI with MET followed by increasing β-cell responsivity with GLY or supplementing with
insulin might be a more optimal strategy for GDM management than monotherapy.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
There are no data describing and comparing the mechanism 
and magnitude of the clinical pharmacological effects of glybur-
ide (GLY), metformin (MET), and GLY and MET (COMBO) 
therapy for gestational diabetes mellitus (GDM).
WHAT QUESTION DID THIS STUDY ADDRESS?
 The objectives of this study were to characterize the pharma-
codynamic (PD) effects of GLY, MET, and COMBO therapy 
for GDM management; evaluate the effects of gestational age
on insulin sensitivity (SI), β-cell responsivity, and disposition 
index (DI); and evaluate the effects of genotype on MET PD 
during pregnancy.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 This is the first study to describe the PD of GLY, MET, and 
COMBO therapy in women with GDM as well as to report the 
effects of MATE2-K on MET’s PD response (change in SI), 
OCT2 on MET dose, and PMAT on MET’s effect on peak  
glucose concentrations during pregnancy.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
Based on the clinical pharmacology gained in this study, 
maximizing MET and thereby SI first and then adding GLY
to increase β-cell responsivity or adding insulin would be a 
more rational approach to GDM treatment. Further research is 
needed prior to making this a clinical recommendation.
Insulin resistance and compensatory increase in insulin concen-
trations occur during normal pregnancy. Although insulin se-
cretion does increase across gestation in women with gestational 
diabetes mellitus (GDM), there is an overall decreased ability to 
compensate for the degree of insulin resistance that occurs, lead-
ing to elevated blood glucose.1,2 If inadequately treated, GDM 
poses significant risks to the mother, fetus, and neonate.3,4 The 
American College of Obstetricians and Gynecologists (ACOG) 
recommends that all pregnant women be screened for GDM be-
tween 24 and 28 weeks gestation and on entry to prenatal care for 
those with risk factors.5
Treatments for women with GDM include dietary changes and 
pharmacotherapy. Historically, insulin has been the first-line ther-
apy, but oral glucose-lowering drugs, such as metformin (MET) 
and glyburide (GLY) have increased in popularity because of their 
ease of administration, lower cost, and comparable efficacy to insu-
lin.6,7 Recent GDM recommendations from ACOG4 exclude GLY 
from first-line oral treatment due to concerns regarding neonatal 
hypoglycemia and macrosomia. GLY, a second-generation sulfony-
lurea, increases insulin release.8 MET, an insulin sensitizer, lowers 
glucose concentrations by suppressing hepatic glucose production, 
decreasing glucose absorption, and increasing peripheral glucose 
uptake and utilization.9 A meta-analysis reported that MET was 
associated with more rapid glucose control and lower postprandial 
glucose concentrations, whereas GLY was associated with lower 
fasting glucose concentrations and hemoglobin A1Cs.10 Data are 
limited regarding the pharmacodynamics (PDs) of GLY and MET 
during pregnancy.
Biomathematical models, such as the oral minimal model of glu-
cose and C-peptide kinetics, have been developed to describe the 
dynamic temporal relationship among serum glucose, insulin, and 
C-peptide concentrations in response to the oral glucose tolerance 
test (OGTT) and the mixed meal tolerance test (MMTT).11–13 
Insulin sensitivity (SI), β-cell responsivity, and disposition index 
(DI) have been utilized as quantitative indices to characterize the 
overall metabolic state in pregnant and nonpregnant individu-
als.11,14,15 Many factors contribute to glucose homeostasis; how-
ever, insulin secretion and action are the primary elements that 
determine response to glucose exposure and thereby glucose tol-
erance. The insulin secretory pathway is complex and regulated
by multiple factors. Pancreatic β-cell function encompasses those 
processes leading to the release of insulin in response to elevated 
glucose concentrations. Exposure of β-cells to an abrupt increase 
of glucose elicits biphasic insulin secretion. The first phase in-
volves the release of immediately available insulin-filled vesicles 
through exocytosis, the rate of which is defined as dynamic β-cell 
responsivity. It describes insulin secretion driven by the rate of 
change in glucose concentrations. The second phase involves the 
mobilization of reserved insulin granules to the cell membrane 
and their subsequent release, the rate of which is defined as static 
β-cell responsivity. It describes insulin secretion primarily driven 
by glucose concentrations. Total β-cell responsivity is controlled by 
both the static and dynamic components, as well as baseline β-cell 
responsivity, which represents the basal, nonstimulated index of 
insulin secretion. SI is a measure of the cascade of insulin actions 
needed to increase glucose utilization and suppress hepatic glucose 
production. Insulin resistance is a state of reduced SI, which can 
stem from defects in glucose transport as a result of impairments in 
translocation, fusion, exposure, or activation of GLUT-4 glucose 
transporters. DI describes the overall metabolic state and is a prod-
uct of SI and total β-cell responsivity. It is an index of β-cell func-
tion, which takes into account the degree of insulin resistance. SI 
and total β-cell responsivity are hyperbolically related (i.e., reflect-
ing the regulated feedback mechanisms that exist between blood 
glucose and insulin).16 These indices provide a mechanistic under-
standing of the patients’ underlying disease pathology and response 
to pharmacotherapies.
Most oral GDM treatment strategies utilize either GLY or MET 
alone. However, the failure rates for individual agents are high 
(14–21% for GLY and ~ 40% for MET).6,17–22 Considering the 
heterogeneous pathology of GDM (differing insulin resistance 
and/or β-cell dysfunction) and the different mechanisms of action 
for GLY and MET, some individuals might benefit from GLY or 
MET monotherapies and some might require GLY and MET com-
bination (COMBO) therapy to optimize glycemic control. The 
objectives of this study were to (i) characterize the PD effects of 
GLY, MET, and COMBO in the management of GDM as deter-
mined by response to the oral MMTT; (ii) evaluate the effects of 
gestational age on SI, β-cell responsivity, and overall DI in healthy 
pregnant (HP) women; and (iii) evaluate the effects of genotype 
on MET PD response during pregnancy.
MATERIALS AND METHODS
Subjects
This was a multicenter, prospective, randomized, nonblinded phase I/
II longitudinal PD study (clinicaltrials.gov identifier NCT01329016). 
The study was approved by the institutional review boards at the 
University of Washington, Madigan Army Medical Center, University 
of Texas Medical Branch in Galveston, University of Pittsburgh, Indiana 
University, University of Utah Health Care, University of Alabama at 
Birmingham, and RTI International, and conducted in accordance with 
their guidelines. All subjects gave written, informed consent. There were 
two groups of women recruited for this study: pregnant women with a 
diagnosis of GDM (n = 109) and HP women (n = 30).
Entry criteria
GDM entry criteria included: pregnant women prior to 32 weeks gestation, 
singleton pregnancy, 18–45 years of age, failed diet therapy and required 
drug treatment. GDM diagnosis was made in one of three ways: (i) 3-hour 
OGTT (100 g glucose orally with two or more values meeting or exceed-
ing targets: fasting ≥ 95 mg/dL, 1-hour ≥ 180 mg/dL, 2-hours ≥ 155 mg/
dL and 3-hours ≥ 140 mg/dL), (ii) 2-hour OGTT (75 Gm glucose orally 
with one or more values meeting or exceeding targets: fasting ≥ 92 mg/dL, 
1-hour glucose ≥ 180 mg/dL, 2-hour glucose > 153 mg/dL), or (iii) 1-hour 
OGTT (50 Gm glucose orally with 1-hour glucose ≥ 185). Exclusion crite-
ria for women with GDM included: medications expected to interact with 
GLY or MET, medications expected to alter blood glucose concentrations, 
serum creatinine  >  1.2  mg/dL; hematocrit  <  28%; allergy to glyburide, 
metformin, or sulfa-drugs; significant liver disease; congestive heart failure 
or history of myocardial infarction; moderate to severe pulmonary disease; 
and adrenal or pituitary insufficiency. Healthy pregnant women entry cri-
teria included: singleton pregnancy, 18–45  years of age, between 20 and 
32 weeks gestation, and a normal 1-hour or 2-hour OGTT. Exclusion cri-
teria for HP women included: hematocrit < 28% or known kidney, liver, 
heart, pulmonary, adrenal, or pituitary disease as well as drugs that alter 
glucose concentrations.
an unpaired Student’s t-test or analysis of variance. A χ2 test was used to
compare race and ethnicity between study arms. Results are reported as 
mean ± SD (95% confidence interval). No adjustments for multiple test-
ing were performed. All statistical analyses and graphs were done in R.29,30
RESULTS
Demographics
Demographics for adherent subjects who completed the study 
are reported in Table 1. Notably, healthy pregnant women were 
significantly younger and weighed less than those with GDM. 
Demographics for all subjects can be found in Supplemental 
Table S1. Nineteen subjects with GDM completed SD1, but not 
SD2. Reasons for withdrawal included: three were lost to fol-
low-up, seven went into early delivery, one had scheduling diffi-
culties, one had medication nonadherence, one became ineligible, 
three started alternate therapy, one experienced anxiety with 
blood draws, one transferred care, and one is unknown. Results 
are reported for adherent subjects who completed the study.
Glucose, insulin, and C-peptide concentrations
Average serum concentration-time profiles for glucose, insulin, 
and C-peptide during a 4-hour MMTT on SD1 and SD2 (during 
treatment for subjects with GDM) are shown in Figure 1 for 
GDM and HP groups. Mean glucose AUCs were lower on SD2 
in the COMBO (P < 0.001) and MET (P = 0.004) groups, and 
not significantly different in the GLY (P = 0.5) and HP (P = 0.8) 
groups. Mean insulin AUCs were lower for the MET group on 
SD2 than SD1 (P = 0.02) but not significantly different in any 
other groups. Mean C-peptide AUCs were similar before and 
with treatment in the COMBO (P  =  0.3) and MET groups 
(P = 0.2). However, GLY and HP groups had higher C-peptide 
AUCs on SD2 than SD1 (GLY P = 0.01; HP P < 0.001).
Gestational age-dependent changes
The hyperbolic relationship between total β-cell responsivity and 
SI in HP women is shown in Figure 2. From SD1 (30 ± 1 weeks 
gestation) to SD2 (36 ± 1 weeks gestation), the hyperbolic mean 
DI curve shifted down and to the left. Baseline β-cell responsiv-
ity increased by an average of 31% (P < 0.001) and overall DI de-
creased by 6% (P = 0.04) between SD1 and SD2 (Table 2). Other 
parameters were not significantly different between study days.
PD parameters
All SD2 PD parameters for subjects with GDM are adjusted 
for gestational age. The mean hyperbolic relationships between 
total β-cell responsivity and SI for HP women and women with 
GDM on SD1 are depicted in Figure 3. The vectors on the 
graph depict the mean PD effects of GLY, MET, and COMBO 
therapy in subjects with GDM. MMTT PD parameters for sub-
jects with GDM are reported in Table 3.
In the GLY group, dynamic β-cell responsivity decreased by 
an average of 31% (P < 0.001), whereas baseline β-cell respon-
sivity increased by 62% (P  =  0.03) and DI 119% (P  =  0.04). 
No significant effects were seen in other PD parameters. In 
the MET group, SI increased by 121% (P  =  0.005); DI 203% 
(P = 0.003), total β-cell responsivity 31% (P = 0.04), and static 
Diagnosis and treatment
Subjects with GDM were randomized to GLY, MET, or COMBO, and 
initial dosage and escalation were determined per treatment algorithms 
as seen in Supplemental Figures S2–S4. Provider discretion was al-
lowed. Blood glucose concentrations were considered controlled when 
≥ 75% of fasting glucose concentrations were ≤ 95 mg/dL and ≥ 75% 
of either 1-hour postprandial glucose concentrations were < 140 mg/
dL or 2-hour postprandial glucose concentrations were < 120 mg/dL. 
Glyburide initial dosage was 2.5 mg orally twice daily. Doses were ti-
trated until glucose concentrations were considered controlled with 
maximum dosage of 8.75 mg orally 3 times daily. MET initial dosage 
was 500 mg twice daily and titrated to clinical control. In the COMBO 
group, subjects received 2.5 mg of GLY and 500 mg of MET twice daily 
initially and titrated to clinical control. If subjects did not achieve gly-
cemic control by titration of dosage according to their treatment al-
gorithm, then subjects completed study day 2 (SD2) and medications 
were switched or adjusted per provider’s preference. Treatment was ini-
tiated at ≤ 32 weeks of gestation. GLY and MET administrations were 
not controlled for fasting or fed conditions except on SD2. On SD2, 
GLY and/or MET were administered simultaneously with initiation 
of the MMTT. Subjects were determined to be nonadherent if they did 
not adhere to their treatment regimen based on study pill count or phy-
sician clinical impression or did not follow study protocol.
MMTT
PD parameters were estimated prior to study day 1 (SD1) and during 
treatment (SD2) utilizing an MMTT consisting of one can of Boost Plus 
energy drink, two slices of whole wheat toast, and two teaspoons of mar-
garine, which was consumed within 10 minutes. SD2 took place once sub-
jects achieved clinical control or prior to switching therapy if they failed to 
achieve glycemic control. Serial blood samples were collected pre-MMTT 
(time = 0), and 10, 20, 30, 60, 90, 120, 150, 180, 210, and 240 minutes fol-
lowing the initiation of the MMTT to measure serum glucose, insulin, and 
C-peptide concentrations. Glucose concentrations were measured using a 
glucose oxidase/peroxidase assay.23 Insulin and C-peptide concentrations 
were measured using previously described radioimmunoassays.24,25
MMTT parameter estimation
Insulin sensitivity, β-cell responsivity, and DI were estimated as previously 
described.11–13,15,26–28 Model parameters were estimated for individual sub-
jects by nonlinear least squares regression using the SAAM II software ver-
sion 2.3 (The Epsilon Group, Charlottesville, VA). Area under the curves 
(AUCs) for glucose, C-peptide, and insulin were calculated utilizing trape-
zoidal rule in R.29 PD response was defined as an increase in PD parameter 
estimates on SD2 relative to SD1 based on the known mechanisms of action 
for the drug (i.e., GLY increases total β-cell responsivity, MET increases 
SI, and COMBO therapy increases either or both parameters). Gestational 
age-matched HP subjects were included in this study to estimate and cor-
rect for gestational age-dependent changes in PD parameters between SD1 
and SD2. The correction for gestational age-dependent effects was accom-
plished by subtracting the average difference between SD2 and SD1 in the 
HP subjects from individual GDM subjects’ SD2 parameters.
Genotyping
DNA was isolated from whole blood, and genotypes were determined 
using validated TaqMan assays. Maternal samples were assayed for 
OCT1: SLC22A1 (rs622342); OCT2: SLC22A2c.808G>T polymor-
phism (rs316019); MATE1: SLC47A1 (rs2289668), and (rs8065082); 
MATE2-K: -130G>A polymorphism (rs12943590); as well as PMAT 
(rs2685753) and (rs6971788).
Statistical analyses
Differences in PD parameter estimates between SD1 and SD2 were esti-
mated using a paired Student’s t-test or between arms of the study using 
Table 1 Demographics and study drug dosing for adherent subjects with gestational diabetes and gestational age-matched 
HP subjects who completed the study
All GDM COMBO GLY MET HP
n 89 32 32 25 28
Race/ethnicity
White, % 81.2 78.1 80.0 82.1
Black, % 9.4 21.9 16.0 17.9
Hispanic, % 34.4 40.6 36.0 32.1
Asian, % 5.6 0 4.0 0
Native American, % 2.8 0 0 0
Age SD1, years 30 ± 5 (19–42) 29 ± 4 (19–37) 30 ± 6 (20–42) 31 ± 4 (22–39) 25 ± 5 (18–38)
(P < 0.001)a
Height SD1, cm 162 ± 6 (147–179) 162 ± 7 (153–175) 161 ± 6 (147–173) 162 ± 6 (147–179) 162 ± 8 (147–178)
Body weight SD1, kg 90 ± 20 (60–200) 100 ± 20 (60–200) 90 ± 20 (60–200) 90 ± 10 (70–100) 80 ± 10 (50–100)
(P < 0.001)a
BMI Pre-pregnancy, kg/m2 33 ± 7 (20–55) 34 ± 8 (22–55) 33 ± 6 (20–53) 31 ± 6 (21–43) 27 ± 5 (20–40)
(P < 0.001)a
GA, SD1, weeks 30 ± 2 (19–33) 30 ± 3 (19–33) 30 ± 2 (24–33) 31 ± 2 (20–33) 30 ± 1 (28–33)
GA, SD2, weeks 35 ± 2 (26–39) 35 ± 3 (26–38) 36 ± 2 (32–39) 35 ± 1 (32–38) 36 ± 1 (34–38)
Glyburide dose SD2, 
mg/day
8 ± 6 (1–30) 6 ± 4 (1–20) 10 ± 6 (2–30) NA NA









BMI, body mass index; COMBO, glyburide plus metformin combination therapy; GA, gestational age; GDM, gestational diabetes mellitus; GLY, glyburide 
monotherapy; HP, healthy pregnant subjects; MET, metformin monotherapy; SD1, study day 1; SD2, study day 2.
aSignificantly different than all GDM subjects, results reported as mean ± SD (range).
Figure 1 Glucose, insulin, and C-peptide concentration-time profiles for all subjects with gestational diabetes mellitus (GDM) and healthy 
pregnant (HP) subjects who completed the study and were adherent to study procedures. Shown are mean concentrations at each time point 
with the SD represented by unidirectional error bars. Time since initiation of the mixed-meal tolerance test and dose in minutes is listed on 
the x axis and the concentration of C-peptide (pM), glucose (mg/dL), or insulin (µU/mL) is on the y axis. Data for study day 1 are shown with 
filled circles (means), solid lines, and upper error bars (SD); data for study day 2 are shown with open circles, dashed lines, and lower error 
bars. Treatment arms are represented by COMBO = metformin/glyburide combination therapy group (green), MET = metformin monotherapy 
group (purple), and GLY = glyburide monotherapy group (blue), and HP group (black). Significance is indicated by asterisks.
β-cell responsivity 33% (P  =  0.04), whereas baseline β-cell re-
sponsivity decreased 28% (P  =  0.004), and MMTT peak glu-
cose concentration 7% (P  =  0.006). There was no significant 
effect on dynamic β-cell responsivity. In the COMBO group, 
SI increased by 83% (P  =  0.03), total β-cell responsivity 57% 
(P  =  0.004), static β-cell responsivity 72% (P  =  0.002), and 
DI 224% (P < 0.001). No significant effects were seen in other 
PD parameters. The change in DI for all GDM subjects taking 
MET, combining those in the MET and COMBO groups, was 
greater than for the GLY group (P = 0.05).
Distributions for changes in PD parameters are depicted in 
Supplemental Figure S1. In the subjects with GDM, 56% of 
subjects in the GLY and 74% of subjects in the COMBO group 
exhibited some pharmacologic response to GLY (increase in 
total β-cell responsivity). In addition, 84% of subjects in the 
MET group and 74% of subjects in the COMBO group exhib-
ited pharmacologic response to metformin (increase in SI). In 
the COMBO group, pharmacologic response to either GLY 
and/or MET (increase in total β-cell responsivity and/or SI) 
was seen in 90% of subjects and pharmacologic response to 
both GLY and MET (increase in total β-cell responsivity and 
SI) was seen in 58%.
Dosage
Table 1 includes average GLY and MET dose/day on SD2 for 
subjects with GDM in the COMBO, GLY, and MET groups. 
Mean GLY dose/day was higher in the GLY group than in the 
COMBO group (P = 0.005). The mean MET dose/day was nu-
merically higher in the MET group than in the COMBO group 
but failed to achieve significance (P = 0.1).
Effect of genotype on MET PD response and MET dose
Figure 4a–c depicts the association among MET transporters—
MATE2-K, PMAT, and OCT2 genotypes and MET response or 
dose.
MATE2-K and metformin’s effect on SI
Women with GDM with MATE2-K (rs12943590; G>A) AA 
genotype had a smaller change in SI with MET than those with 
MATE2-K GG genotype (Figure 4a; P = 0.03).
Figure 2 Effect of gestational age on the mean disposition index 
in healthy pregnant (HP) subjects. Only paired data for HP subjects 
who completed study day 1 (SD1) and study day 2 (SD2) are included 
(n = 28). Insulin sensitivity (SI) is depicted on the x axis, and total 
β cell responsivity is depicted on the y, and points depict the mean
total β-cell responsivity and mean SI on SD1 (filled circle) and SD2
(open circle) for the HP group. The hyperbolas shown depict the 
calculated total β-cell responsivity given the range of SI values shown
for HP on SD1 (solid line) and SD2 (dashed line) where total β-cell
responsivity = DI
SI
 and the DI value used was the mean total β-cell
responsivity times the mean SI.
Table 2 Mixed meal tolerance test parameters for HP control subjects SD1 (baseline) and SD2
HP (n = 28)
Parameter SD1 SD2 Δ
SI (10−4 minute−1 µU−1 mL) 8 ± 6 (2–20) 7 ± 4 (1–20) –0.8 ± 4 (−9 to 6)
(P = 0.6)
Φtotal (10
−9 minute−1) 120 ± 60 (51–280) 110 ± 40 (46–190) −10 ± 50 (−100 to 20)
(P = 0.1)
Φstatic (10





3,000 ± 1,000 (1,000–5,000) 2 ± 1,000 (−2,000 to 2,000)
(P = 1)
Φbaseline (10
−9 minute−1) 10 ± 4 (4.3–20) 14 ± 6 (6.2–26) 3 ± 3 (−0.2 to 9)
(P < 0.001)
DI (10−13 minute−2 µU−1 mL) 800 ± 500 (200–2,000) 600 ± 300 (200–1,000) −200 ± 400 (−1,000 to 400)
(P = 0.04)
Peak glucose (mg/dL) 120 ± 20 (94–150) 120 ± 10 (96–150) −0.7 ± 10 (−30 to 10)
(P = 0.8)
Results reported as mean ± SD (95% confidence interval).
Δ, average change between study day 1 and study day 2; Φ, β-cell responsivity; DI, disposition index; SD1, study day 1; SD2, study day 2; SI, insulin sensitivity.
PMAT and MET effect on peak glucose concentration
PMAT (rs2685753 G>A) AG genotype was associated with a 
larger decrease in MMTT peak glucose concentrations than GG 
genotype (Figure 4b; P = 0.03).
OCT2 effect on MET dose
Women with OCT2 (rs316019) AC genotype, on average, re-
quired a higher MET dose than those with OCT2 CC geno-
type (Figure 4c; P = 0.001). There were no subjects with AA 
genotype.
In this study, MATE1, PMAT, OCT1, and OCT2 genotypes 
were not associated with MET pharmacologic effect (change 
in SI); MATE1, MATE2-K, PMAT, and OCT1 genotypes 
were not found to significantly affect MET dose; and MATE1, 
MATE2-K, OCT1, and OCT2 genotypes did not alter met-
formin’s effect on MMTT peak glucose concentrations.
DISCUSSION
The majority of medication prescribing during pregnancy is based 
on clinical trials in the nonpregnant population. The mechanism 
and magnitude of pharmacologic response to GLY and MET have 
not been described during pregnancy despite the significant alter-
ations in glucose and insulin handling that occur during normal 
pregnancy. This study is the first to (i) quantify and compare the 
PD effects of GLY, MET, and COMBO treatment in pregnant 
women with GDM, and (ii) report the effects of MATE2-K on 
metformin’s PD response (change in SI), OCT2 on MET dose, 
and PMAT on MET’s effect on peak glucose concentrations 
during pregnancy.
Most healthcare providers who prescribe oral glucose-lowering 
agents for women with GDM currently use either MET or GLY 
monotherapies, with significant failure rates.22. This may occur for 
two reasons. First, evidence suggests GLY and MET exposures are 
reduced during pregnancy11,31; therefore, utilizing dosage strategies 
established in nonpregnant individuals might not be appropriate. 
For this reason, GLY dosage up to 8.75 mg orally 3 times daily was 
allowed in this study. Second, the underlying pathology of GDM is 
heterogeneous with respect to β-cell dysfunction and insulin resis-
tance. Monotherapies that treat only one facet of GDM pathology 
may not be as effective as a combination approach. The vectors de-
picted in Figure 3 demonstrated the average response to each ap-
proach. As expected, GLY (average dose: 10 mg/day) exhibited its 
effects primarily through β-cell responsivity and produced a small 
average DI vector. Although MET (average dose: 1,400  mg/day) 
improved SI as expected, it also improved β-cell responsivity. The 
addition of GLY (average dose: 6 mg/day) to MET (average dose: 
1,200 mg/day) in the COMBO group boosted the average effect on 
β-cell responsivity, but had less effect on SI than the MET group, as 
the dose of MET in the COMBO group was, on average, 200 mg/
day lower. Interestingly, none of the drug treatment vectors moved 
the average DI back to what would be considered normal in preg-
nancy. Given the hyperbolic nature of the DI curve and where the 
women with GDM started at baseline, the treatments that improved 
SI most moved the subjects closer to a normal DI than those that 
primarily affected β-cell responsivity (i.e., the change in DI for 
women with GDM taking MET in the MET and COMBO groups 
was greater than in those taking GLY). The majority of women with 
GDM initiated treatment with a DI on the steep ascending portion 
Figure 3 Pharmacodynamic effects of glyburide (GLY), metformin (MET), and GLY/MET combination (COMBO) therapies. Gray line depicts 
the mean baseline disposition index for all adherent subjects with gestational diabetes mellitus (GDM) who completed the study. The black 
line depicts the mean baseline disposition index for all healthy pregnant (HP) subjects who completed the study. The vectors depict the 
mean pharmacodynamic effect of GLY (blue arrow), MET (purple arrow), and GLY/MET COMBO therapy (green arrow). Solid dots represent 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of the hyperbolic DI curve, making GLY (i.e., altering β-cell respon-
sivity alone) far less successful in normalizing overall DI. This sug-
gests that maximizing MET and thereby SI first and then adding 
GLY to increase β-cell responsivity or adding insulin supplementa-
tion would be a more rational approach to managing patients with 
GDM. Further research is needed prior to making this a clinical rec-
ommendation. However, this is consistent with recent ACOG rec-
ommendations for women who decline insulin to use MET as the 
first-line alternative oral agent.4
In this study, the percent of subjects having some pharmacologic 
response (i.e., improvement in either SI and/or total β-cell respon-
sivity) differed by treatment arm. Fifty-six percent of the GLY 
group, 84% of the MET group, and 90% of the COMBO group 
had some pharmacologic response to GLY and/or MET. Both 
COMBO and MET were associated with significant reductions 
in MMTT average glucose exposure, whereas GLY, on average, 
was not (Figure 1). The Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) study found a strong association between 
higher maternal glucose concentrations in response to an OGTT 
and higher risk of pregnancy complications from GDM.32 This 
supports the merit of clinical trials exploring comparative efficacy 
of MET either alone or in combination.
Consistent with the expected effect of GLY, average MMTT 
C-peptide concentrations were higher in the GLY group with
treatment than before treatment (Figure 1). Although insu-
lin concentrations were numerically higher with GLY, this did
not reach statistical significance. Interestingly, in the COMBO
group, neither average C-peptide nor insulin concentrations
were significantly higher, perhaps due to the lower GLY dosage
in the COMBO group than in the GLY group (6 vs. 10 mg/day,
Figure 4 Effects of a splice variant of multidrug and toxin extrusion transporter 2 (MATE2-K) and organic cation transporter 2 (OCT2) genotype 
on metformin response and dose in women with gestational diabetes mellitus GDM who were adherent and completed the study. (a) Depicts 
a Tukey boxplot of the effects of MATE2-K genotype (rs12943590; AA, AG, and GG) on metformin (MET) pharmacologic activity (i.e., change in 
insulin sensitivity between study day 1 (SD1) and study day 2 (SD2), adjusted for gestational age-dependent changes) in women receiving MET 
monotherapy. (b) Depicts a Tukey boxplot of the effects of PMAT genotype (rs2685753; AG and GG) on change in peak glucose concentrations 
in women receiving MET monotherapy. (c) Depicts a Tukey boxplot of the effects of OCT2 genotype (rs316019, AC vs. CC) on MET dose on SD2 
in women receiving MET monotherapy. *P < 0.05, **P < 0.01, and ***P < 0.001.
P = 0.005). Even so, average vector plots seem to show a small 
additional increase in β-cell responsivity in the COMBO group 
over the MET group, although this was not statistically signifi-
cant (Figure 3). In the MET group, insulin concentrations were 
significantly lower with treatment than before treatment, re-
flecting MET’s impact on SI and, thus, resulting in a lesser need 
for insulin and decreasing the demands on the pancreas.
Buchanan previously described the hyperbolic relationship be-
tween insulin secretion rate and SI in normal women and women 
with GDM in the third trimester of pregnancy and postpartum. 
Similar to our findings, he depicted the population with GDM 
to have a lower-than-normal DI. Interestingly, Buchanan de-
picted both pregnant and nonpregnant DI on the same curve.33 
Subsequently, Buchanan’s group published a 4-year longitudinal 
study describing declining DI in women with and without GDM, 
noting a faster decline in DI in individuals with GDM.34 In our 
study, “normal” pregnant women (i.e., those having normal values 
during their OGTT screening for GDM) had a 6% decline in their 
DI over an average of 5.5 weeks between SD1 and SD2 (mean dif-
ference: –200 ± 400 × 10−13 minute−2 µU−1 mL; P = 0.04). This 
decreased ability to compensate for the degree of insulin resistance 
as pregnancy progresses, even among those who are “normal,” aligns 
with the continuum of GDM described in the HAPO study and 
calls for careful consideration and standardization of diagnosis.32
Multiple bidirectional drug transporters are involved in the dispo-
sition of MET, including organic cation transporters 1–3 (OCT1, 
OCT2, and OCT3), as well as multidrug and toxin extrusion trans-
porters 1, 2, and 2-K (MATE1, MATE2, and MATE2-K). OCT 
transporters and PMAT along with the MATE transporters work 
in series to move MET across the cell.35–37 MATE2-K (rs12943590 
G>A) genetic variant is associated with increased promoter activ-
ity in vitro.38,39 In vivo, some but not all studies have reported that 
MATE2-K rs12943590 G>A genetic variant has been associated 
with increased MET renal clearance and decreased MET efficacy. 
We are the first to report the effect of MATE2-K on MET PD (i.e., 
the effect on SI following an MMTT). Consistent with reports of 
MATE2-K rs12943590 G>A genetic variant’s impact on transporter 
activity, we found that women with GDM and MATE2-K AA geno-
type had a smaller increase in SI with MET than those with GG gen-
otype (Figure 4a).40,41
In addition, women with GDM and OCT2 (rs316019) AC gen-
otype required a higher MET dose than those with OCT2 CC gen-
otype. Previously, it had been reported that the OCT2-808T genetic 
variant was associated with increased activity compared with the 
OCT2 reference in stably transfected HEK-293 cells in vitro.42 There 
are mixed reports on the effect of the OCT2 rs316019 A>C genetic 
variant on metformin disposition in vivo.43–47 It has been previously 
reported that individuals’ heterozygous for the OCT2 variant allele 
(808G/T) had higher MET renal clearance than those homozygous 
for the OCT2 reference allele (808G/G) in white volunteers.35 In 
contrast, two studies in Asian volunteers reported the opposite effect 
(i.e., those heterozygous for OCT2 variant allele (808G/T) had lower 
MET renal clearance than those homozygous for OCT2 reference al-
lele (808G/G)).46,47 In this study, we did not find an association with 
OCT2 genotype and SI, but did find a relationship between OCT2 
genotype and metformin dose. This is somewhat surprising given that 
during pregnancy we found no association with OCT2 genotype and 
metformin renal clearance.48 The explanation for this discrepancy is 
unclear. However, dosage is definitely a more confounded end point 
due to provider discretion than renal clearance or SI.
Last, there are conflicting results with respect to the effects 
of the PMAT (rs2685753 G>A) variant genotype and its asso-
ciation with MET exposure.49,50 Our results demonstrated that 
pregnant woman with GDM and the PMAT (rs2685753 G>A) 
AG genotype had a greater decrease in the MMTT peak glucose 
concentrations than those with GG genotype (P = 0.03). PMAT 
was not significantly associated with changes in metformin PD 
(change in SI) or metformin pharmacokinetics,48 which calls 
into question the mechanism by which PMAT genotype affected 
metformin’s effect on MMTT peak glucose concentrations.
Limitations
With respect to the genetics portion of this study, the sample size is 
small to draw definitive conclusions with respect to the role of trans-
porter genotypes in PD effects of MET. Larger studies are needed 
to explore the genetic associations with the biology of response.
In summary, this study, we believe for the first time, characterized 
the PD effects of GLY, MET, and COMBO treatment in women 
with GDM. Individual PD responses were variable, and none of the 
treatment approaches fully normalize the overall glycemic response. 
However, those that included MET shifted the overall DI closer to 
normal than those that primarily increased β-cell responsivity due to 
the hyperbolic shape of the DI curve and baseline parameters in the 
women with GDM. This suggests that maximizing MET and thereby 
SI first and then adding GLY to increase β-cell responsivity or add-
ing insulin would be a more rational approach. Last, in the pregnant 
women with GDM, associations were found between MATE2-K 
genotype and MET’s pharmacologic effect, OCT2, and MET dosage 
as well as PMAT and MET’s effect on peak glucose concentrations.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. Changes in pharmacodynamic parameters with drug treat-
ment of GDM. Histograms of the distribution of changes in total β -cell
responsivity (Φtotal), SI, and DI for subjects receiving either COMBO
(green), GLY (blue), or MET (purple) for the treatment of GDM adjusted 
for gestational age-dependent changes. Bar height indicates number of 
subjects. Zero, indicated with a vertical red line, represents no change.
Figure S2. Glyburide monotherapy dosage titration. This figure de-
picts the study guide for glyburide monotherapy dosage titration. 
Starting dosage was glyburide 2.5 mg orally twice daily and was ti-
trated as high as 8.75 mg orally three times daily. Provider’s discre-
tion was allowed. In addition, this figure depicts when SD2 MMTT 
should be completed. po, orally; bid, twice daily; tid, three time daily; 
PD, pharmacodynamic.
Figure S3. Metformin monotherapy dosage titration. This figure depicts 
the study guide for metformin monotherapy dosage titration. Starting 
dosage was metformin 500 mg orally twice daily and was titrated as 
high as 2,000 mg/day in divided doses. Provider’s discretion was al-
lowed. In addition, this figure depicts when study day 2 MMTT should 
be completed. po, orally; bid, twice daily; tid, three time daily; qid, four 
times daily; PD, pharmacodynamic.
Figure S4. Glyburide and metformin combination therapy dosage titra-
tion. This figure depicts the study guide for glyburide and metformin 
dosage titration in the combination therapy group. Starting glyburide 
dosage was 2.5 mg orally twice daily and titrated as high as 10 mg 
orally twice daily. Starting metformin dosage was 500 mg orally twice 
daily and titrated as high as 2,000 mg/day in divided doses. Provider’s 
discretion was allowed. In addition, this figure depicts when study day 
2 MMTT should be completed. po, orally; bid, twice daily; tid, three time 
daily; qid, four times daily; PD, pharmacodynamic.
Table S1. Demographics of all eligible subjects with gestational diabe-
tes and gestational age-matched healthy pregnant subjects.
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